Could a Heart Drug Combo Help Reverse Fatty Liver Disease?

In bustling urban centers across the globe, a silent crisis looms—a chronic condition that could be lurking in the shadows of millions of otherwise healthy adults. Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as nonalcoholic fatty liver disease, is now the most common chronic liver condition, impacting nearly 40% of adults worldwide. As the sun sets over these cities, people may be enjoying life, unaware that this silent ailment can pave the way for severe complications like cirrhosis and liver cancer.

The Hidden Epidemic of MASLD

The prevalence of MASLD has surged in recent decades, and its rise correlates ominously with increasing rates of obesity and sedentary lifestyles. This disease is particularly insidious; it often appears without symptoms until it has progressed to critical stages. “Many people are completely unaware they have MASLD until it’s too late,” shares Dr. Helena Garcia, a hepatologist at the University of Madrid. “We are talking about a condition that, if neglected, can lead to irreversible damage to the liver.”

The Risks and Challenges of Treatment

One of the primary challenges of managing MASLD is the limited availability of targeted pharmacological treatments. Beyond lifestyle changes, such as weight loss—which studies suggest can reduce liver fat effectively—there are scant options for early interventions. “Typically, mere weight loss of about 3-5% can alleviate the condition,” observes Dr. Susan Ellison, an expert in metabolic diseases. “But not everyone can achieve or maintain that, which is where our predicament lies.”

To explore new avenues, researchers are investigating existing medications that could be repurposed to combat MASLD effectively. Recent studies indicate promise with two well-known heart medications—pemafibrate and telmisartan—both of which have shown significant efficacy in reversing fat accumulation in the liver of animal models.

A Breakthrough Study on Heart Drugs

In a pioneering study conducted by the University of Barcelona, researchers utilized dietary rat models that mimic early-stage MASLD, focusing on simple steatosis without the presence of inflammation or fibrosis. “These initial phases are often brushed aside as benign, but they pose significant risks,” notes Marta Alegret, DPharm, one of the lead authors.

• The study employed two animal models: rats and zebrafish larvae.
• Rats were divided into groups, with one receiving high-fat diets and the other standard diets.
• Three groups were administered different dosages of pemafibrate and telmisartan over a three-month period.

At the conclusion of the experiment, results were illuminating. Both drugs not only reduced liver triglyceride levels but, intriguingly, the combination at half the typical doses was just as effective. “This finding could have profound implications for how we approach treatment,” remarked Alegret. “Lower doses mean we could mitigate the risks of adverse effects while still achieving therapeutic outcomes.”

Mechanisms of Action

Pemafibrate is known to enhance lipid catabolism, while telmisartan impacts endogenous lipid synthesis pathways. “When used together, they effectively counteract the dual aspects of MASLD: fat buildup and cardiovascular risk,” explains Dr. Cheng-Han Chen, a cardiologist at MemorialCare Saddleback Medical Center. “This combination could potentially benefit a demographic that already faces heightened cardiovascular challenges.”

Interestingly, these drugs are currently utilized in treating cardiovascular diseases, and their safety profiles are well-established, making them prime candidates for repurposing. Dr. Chen highlights, “The pharmaceutical landscape is littered with compounds that never reach the market due to safety concerns. Finding new applications for existing medications can be a transformative and cost-effective strategy.”

Progress Toward Clinical Trials

Despite the optimistic findings, experts are cautious. The journey from rodent models to human trials is fraught with complexities. “Our results are promising, but we cannot recommend these drugs for MASLD treatment just yet,” Alegret emphasizes. “Clinical trials with larger cohorts and robust endpoints are necessary to validate these findings.” She indicates that while smaller studies have hinted at improvements in MASLD markers using either drug, comprehensive assessments are required for regulatory approval.

The gravity of MASLD cannot be overstated. As Dr. Ellison warns, “Ignoring the rising tide of this disease means risking a public health crisis that could result in a surge of liver-related complications down the line.” Should the promising data surrounding pemafibrate and telmisartan hold true through rigorous clinical testing, a new chapter in the treatment of liver disease may well be on the horizon.

As researchers dive deeper into this urgent problem, the hope is that the intersection of cardiology and hepatology will yield breakthroughs that could change lives. For now, the race is on to conduct the necessary trials that might make a significant difference for millions silently battling the effects of MASLD.

Source: www.medicalnewstoday.com